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Patients and physicians may defer unrelated donor hematopoietic cell transplantation (HCT) as curative
therapy because of the mortality risk associated with the procedure. Therefore, it is important for physicians
to know the current outcomes data when counseling potential candidates. To provide this information, we
evaluated 15,059 unrelated donor hematopoietic cell transplant recipients between 2000 and 2009. We
compared outcomes before and after 2005 for 4 cohorts: age <18 years with malignant diseases (n ¼ 1920),
ages 18 to 59 years with malignant diseases (n ¼ 9575), ages  60 years with malignant diseases (n ¼ 2194),
and nonmalignant diseases (n ¼ 1370). Three-year overall survival in 2005 to 2009 was signiﬁcantly better in
all 4 cohorts (<18 years: 55% versus 45%, 18 to 59 years: 42% versus 35%, 60 years: 35% versus 25%,
nonmalignant diseases: 69% versus 60%; P < .001 for all comparisons). Multivariate analyses in leukemia
patients receiving HLA 7/8 to 8/8ematched transplants showed signiﬁcant reduction in overall and non-
relapse mortality in the ﬁrst year after HCT among patients who underwent transplantation in 2005 to 2009;
however, risks for relapse did not change over time. Signiﬁcant survival improvements after unrelated donor
HCT have occurred over the recent decade and can be partly explained by better patient selection (eg, HCT
earlier in the disease course and lower disease risk), improved donor selection (eg, more precise allele-level
matched unrelated donors) and changes in transplantation practices.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION donor. Survival after unrelated donor HCT has nearly doubled
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ty for Blood and Marrow Transplantation.since the ﬁrst unrelated donor transplantations in the late
1980s [1,2]. Currently, 1-year survival of 60% to 70% can be
expected for patients with high-risk acute leukemia who
receive an unrelated donor HCT relatively early in their dis-
ease course [3,4]. For some diseases, survival after HLA-
matched unrelated donor transplantation has been shown
to be comparable to HCT using HLA-identical sibling donors
[5-10]. However, patient and physician perceptions of the
risks and efﬁcacy of unrelated donor transplantation may
prevent some patients from being referred for this
Table 1
Demographic Characteristics by Age, Diagnosis, and Time Period
Characteristic Age <18 Yr, Malignant Diseases Age 18-59 Yr, Malignant Diseases Age 60 Yr, Malignant Diseases Nonmalignant Diseases
2000-2004 2005-2009 P Value* 2000-2004 2005-2009 P Value* 2000-2004 2005-2009 P Value* 2000-2004 2005-2009 P Value*
Recipients, n 904 1016 3827 5748 410 1784 477 893
Centers, n 97 103 138 152 76 115 83 133
Follow-up, median (range), mo 91 (3-147) 47 (4-78) <.001 95 (3-145) 42 (3-84) <.001 76 (9-121) 36 (3-82) <.001 82 (4-147) 39 (2-85) <.001
Recipient gender .90 .03 .07 .20
Female 362 (40) 410 (40) 1618 (42) 2557 (44) 125 (30) 628 (35) 197 (41) 337 (38)
Male 542 (60) 606 (60) 2209 (58) 3191 (56) 285 (70) 1156 (65) 280 (59) 556 (62)
Recipient race/ethnicity .06 .003 .80 .58
White 632 (70) 694 (68) 3324 (87) 4896 (85) 391 (95) 1671 (94) 328 (68) 599 (67)
Hispanic 137 (15) 178 (18) 220 (6) 356 (6) 8 (2) 41 (2) 70 (15) 131 (15)
Black/African American 85 (9) 65 (6) 167 (4) 255 (4) 6 (1) 31 (2) 41 (9) 79 (9)
Asian/Paciﬁc Islander 29 (3) 39 (4) 64 (2) 104 (2) 1 (<1) 17 (1) 28 (6) 47 (5)
American Indian/Alaska Native 4 (<1) 7 (1) 6 (<1) 23 (<1) 0 1 (<1) 1 (<1) 8 (1)
Other/multiple race 10 (1) 22 (2) 22 (1) 31 (1) 1 (<1) 8 (<1) 5 (1) 18 (2)
Declined/unknown 7 (1) 11 (1) 24 (1) 83 (1) 3 (1) 15 (1) 4 (1) 11 (1)
Karnofsky/Lansky score at HCT .005 <.001 <.001 .008
90 to 100 691 (76) 822 (81) 2313 (60) 3521 (61) 236 (58) 1031 (58) 337 (71) 675 (76)
10 to 80 115 (13) 126 (12) 1098 (29) 1853 (32) 120 (29) 639 (36) 101 (21) 180 (20)
Unknown 98 (11) 68 (7) 416 (11) 374 (7) 54 (13) 114 (6) 39 (8) 38 (4)
Recipient CMV status .01 .009 .58 .16
Negative 504 (56) 500 (49) 1698 (44) 2383 (41) 137 (33) 633 (36) 220 (46) 395 (44)
Positive 395 (44) 507 (50) 2097 (55) 3300 (57) 269 (66) 1127 (63) 246 (52) 488 (55)
Unknown 5 (1) 9 (1) 32 (1) 65 (1) 4 (1) 24 (1) 11 (2) 10 (1)
Coexisting disease at HCT 269 (30) 376 (37) <.001 1858 (49) 3644 (63) <.001 296 (72) 1398 (78) .02 196 (41) 443 (50) .008
Diagnosis <.001 <.001 .002 <.001
AML 279 (31) 290 (29) 1409 (37) 2412 (42) 202 (49) 884 (50) - -
ALL 383 (42) 462 (45) 667 (17) 973 (17) 18 (4) 65 (4) - -
CML 85 (9) 44 (4) 620 (16) 421 (7) 20 (5) 32 (2) - -
Other leukemia 26 (3) 32 (3) 230 (6) 381 (7) 38 (9) 193 (11) - -
MDS 57 (6) 99 (10) 355 (9) 634 (11) 59 (14) 293 (16) - -
Myeloproliferative diseases 39 (4) 44 (4) 98 (3) 210 (4) 20 (5) 93 (5) - -
NHL 30 (3) 38 (4) 352 (9) 622 (11) 46 (11) 211 (12) - -
Hodgkin lymphoma 1 (<1) 3 (<1) 24 (1) 48 (1) 0 3 (<1) - -
Plasma cell disorders - - 46 (1) 33 (1) 2 (<1) 7 (<1) - -
Other malignant diseases 4 (<1) 4 (<1) 26 (1) 14 (<1) 5 (1) 3 (<1) - -
SAA - - - - - - 186 (39) 402 (45)
Inherited erythrocyte disorders - - - - - - 95 (20) 137 (15)
Inherited immune system disorders - - - - - - 70 (15) 177 (20)
Inherited disorders of metabolism - - - - - - 71 (15) 59 (7)
Histiocytic disorders - - - - - - 43 (9) 96 (11)
Inherited platelet disorders - - - - - - 10 (2) 8 (1)
Other nonmalignant diseases - - - - - - 2 (<1) 14 (2)
Disease risky .03 <.001 .04
Standard 546 (60) 644 (63) 1632 (43) 2810 (49) 141 (34) 700 (39) - -
High 278 (31) 261 (26) 1740 (45) 2139 (37) 198 (49) 738 (41) - -
Other 80 (9) 111 (11) 455 (12) 799 (14) 71 (17) 346 (19) - -
Time from diagnosis to HCT, mo .03 <.001 .003
0 to 6 259 (29) 360 (35) 862 (23) 1779 (31) 84 (20) 519 (29) - -
6 to 12 195 (22) 191 (19) 1076 (28) 1426 (25) 136 (33) 470 (26) - -
12 to 24 178 (20) 189 (19) 878 (23) 1098 (19) 77 (19) 300 (17) - -
(continued on next page)
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Table 1
(continued )
Characteristic Age <18 Yr, Malignant Diseases Age 18-59 Yr, Malignant Diseases Age 60 Yr, Malignant Diseases Nonmalignant Diseases
2000-2004 2005-2009 P Value* 2000-2004 2005-2009 P Value* 2000-2004 2005-2009 P Value* 2000-2004 2005-2009 P Value*
>24 265 (29) 271 (27) 973 (25) 1394 (24) 111 (27) 478 (27) - -
Unknown 7 (<1) 5 (<1) 38 (1) 51 (1) 2 (<1) 17 (<1) - -
Product type <.001 <.001 <.001 .03
Bone marrow 696 (77) 682 (67) 2021 (53) 1244 (22) 93 (23) 234 (13) 377 (79) 658 (74)
PBSC 208 (23) 334 (33) 1806 (47) 4504 (78) 317 (77) 1550 (87) 100 (21) 235 (26)
Conditioning regimenz <.001 <.001 <.001 <.001
MA, no TBI 93 (10) 272 (27) 739 (19) 2118 (37) 55 (13) 417 (23) 99 (21) 243 (27)
MA, TBI 726 (80) 659 (65) 1912 (50) 1935 (34) 17 (4) 55 (3) 81 (17) 48 (5)
NMA/RIC, no TBI 67 (7) 67 (7) 867 (23) 1329 (23) 212 (52) 933 (52) 140 (29) 280 (31)
NMA/RIC, TBI 18 (2) 18 (2) 309 (8) 365 (6) 126 (31) 379 (21) 157 (33) 322 (36)
Unknown 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0)
HLA matchx <.001 <.001 <.001 <.001
8/8 Allele level 338 (37) 604 (59) 1705 (45) 3890 (68) 202 (49) 1328 (74) 193 (40) 571 (64)
7/8 Allele level 174 (19) 299 (29) 735 (19) 1274 (22) 59 (15) 308 (17) 92 (19) 220 (25)
 6/8 Allele level 162 (18) 80 (8) 426 (11) 180 (3) 26 (6) 16 (1) 86 (18) 62 (7)
Well matched 115 (13) 23 (2) 567 (15) 295 (5) 80 (20) 98 (5) 38 (8) 27 (3)
Partially matched 98 (11) 8 (1) 351 (9) 97 (2) 35 (9) 28 (2) 59 (12) 12 (1)
Mismatched 17 (2) 1 (<1) 43 (1) 12 (<1) 8 (2) 6 (<1) 9 (2) 1 (<1)
Unknown 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
GVHD prophylaxis <.001 <.001 <.001 <.001
TAC þ MMF 22 (2) 78 (8) 387 (10) 1024 (18) 65 (16) 425 (24) 20 (4) 78 (9)
TAC þ MTX (no MMF) 192 (21) 281 (28) 1402 (37) 2881 (50) 116 (28) 692 (39) 62 (13) 171 (19)
TAC þ other (no MMF/MTX) 44 (5) 88 (9) 213 (5) 473 (8) 32 (8) 162 (9) 29 (6) 66 (7)
CSA þ MMF 30 (3) 62 (6) 382 (10) 342 (6) 138 (34) 249 (14) 44 (9) 99 (11)
CSA þ MTX (no MMF) 417 (46) 360 (35) 1133 (30) 602 (10) 28 (7) 87 (5) 160 (34) 282 (32)
CSA þ other (no MMF/MTX) 151 (17) 70 (7) 204 (5) 106 (2) 19 (5) 42 (2) 144 (30) 145 (16)
Other 46 (5) 74 (7) 100 (3) 309 (5) 12 (3) 124 (7) 16 (3) 35 (4)
Unknown 2 (<1) 3 (<1) 6 (<1) 10 (<1) 0 (0) 3 (<1) 2 (<1) 17 (2)
In vivo T cell depletion 370 (41) 482 (47) .02 985 (26) 2086 (36) <.001 156 (38) 820 (46) .01 393 (82) 742 (83) .74
Ex vivo T cell depletion 167 (18) 85 (8) <.001 271 (7) 72 (1) <.001 5 (1) 29 (2) .83 120 (25) 49 (5) <.001
CMV indicates cytomegalovirus; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia; MA, myeloablative; TBI, total body irradiation; TAC, tacrolimus; MMF, mycophenolate mofetil;
MTX, methotrexate; CSA, cyclosporine.
Data presented are n (%) unless otherwise indicated.
* Pearson chi-square test for categorical variables and Kruskal-Wallis test for continuous variables.
y Standard-risk diseases included AML or ALL in ﬁrst or second complete remission, CML in ﬁrst chronic phase, and low-risk MDS. High-risk diseases comprised of AML or ALL in third or greater complete remission, relapse, or
primary induction failure, CML in second or greater chronic, accelerated, or blast phase, high-risk MDS, and NHL. All other diseases were classiﬁed under the other risk category.
z Conditioning regimen intensity was classiﬁed according to CIBMTR criteria [23].
x HLA matching status was classiﬁed as well matched, partially matched, or mismatched in patients for whom high-resolution HLA typing was not available [24].
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outcomes are optimal [11,12]. Several advances in trans-
plantation technology and supportive care have occurred in
recent years and a considerably larger number of HLA-
matched unrelated donors are now available. Analyses of
unrelated donor transplantation outcomes in the contem-
porary period are lacking. To provide an up-to-date analysis
of the risks and beneﬁts of this therapeutic option, we
studied a large cohort of patients who underwent HCT be-
tween 2000 and 2009 facilitated by the National Marrow
Donor Program (NMDP).
METHODS
Data Source
Data were obtained from the Center for International Blood andMarrow
Transplant Research, the research arm of the NMDP. Transplantation centers
in the NMDP network are required to submit patient outcomes data for all
NMDP-facilitated unrelated donor transplantations to the Center for Inter-
national Blood and Marrow Transplant Research. Patients are followed
longitudinally. Computerized checks for discrepancies, physicians’ review of
submitted data, and on-site audits of participating centers ensure data
quality and completeness. This study was performed in compliance with all
applicable federal regulations pertaining to the protection of human
research participants and under guidance of the NMDP Institutional Review
Board.
Study Population
We selected our cohort to enable examination of trends in survival over
a recent period that reﬂected current unrelated donor transplantation
practices. Thus, we included all NMDP-facilitated ﬁrst unrelated donor
transplantations using peripheral blood stem cells (PBSC) or bone marrow
between 2000 and 2009. The NMDP facilitated > 90% of all unrelated donor
HCT in the United States during this time period [13]. Umbilical cord blood
recipients were excluded. Patients from all age groups and with any diag-
nosis were considered, and our cohort consisted of recipients of myeloa-
blative and nonmyeloablative/reduced-intensity conditioning (NMA/RIC)
regimens.
Statistical Analysis
We compared outcomes for 2 5-year periods (2000 to 2004 versus 2005
to 2009). Analyses were conducted for 4 separate groups stratiﬁed by age
and diagnosis because of known differences in survival by these variables
[4]: (1) age < 18 years, malignant diseases (2), age 18 to 59 years, malignant
diseases (3), age  60 years, malignant diseases, and (4) nonmalignant
diseases (all ages). The primary endpoint of our study, overall survival at
3 years, was selected as most deaths will have occurred by this time period
[4]. Nonrelapse mortality (NRM), relapse, acute graft-versus-host disease
(GVHD), and chronic GVHD were secondary endpoints.
Patient-, disease-, and transplantation-related characteristics were
compared using the chi-square test for categorical variables and the
Kruskal-Wallis test for continuous variables. Probability of overall survival
was calculated with the Kaplan-Meier estimator and probabilities of NRM,
relapse, and GVHD were calculated using the cumulative incidence function
[14,15]. Relapse was considered a competing risk for NRM, whereas death in
remission was considered a competing risk for relapse. Where sample size
permitted, we conducted additional subset analyses in more homogeneous
populations that were deﬁned based on variables that routinely affect un-
related donor HCT outcomes, such as relapse risk, conditioning intensity,
and HLA match. To further enhance their utility for clinical decision making,
these subgroups were constructed to reﬂect common clinical scenarios
whenever possible.
We conducted multivariate analyses using Cox proportional hazards
regression to better understand the contribution of changes in patient and
disease characteristics as well as practice factors on survival, NRM, and
relapse [16]. We minimized the impact of factors resulting from changes in
the proportions of diseases that led to transplantation and the introduction
of high-resolution DNA-based tissue typing that occurred during the time
frame studied by restricting this analysis to a more homogenous subset of
patients who had received 7/8 or 8/8 HLAematched graft for selected ma-
lignant diseases (acute myeloid leukemia [AML], acute lymphoblastic leu-
kemia, chronic myeloid leukemia [CML] or myelodysplastic syndromes
[MDS], n ¼ 8531). Models were constructed in 2 steps. The initial models
were adjusted for patient and disease characteristics. Variables considered
included patient age at HCT, gender, ethnicity/race, Karnofsky/Lansky per-
formance score, cytomegalovirus serological status, coexisting diseases,
diagnosis, time since diagnosis, and disease risk. In the second step,variables that represented changes in transplantation practices were
introduced. These included HLA match, graft type, conditioning intensity,
GVHD prophylaxis regimens, and use of T cell depletion. Patient and disease
characteristics noted to be signiﬁcant in the ﬁrst model remained signiﬁcant
in the subsequent model that adjusted for transplantation practice factors.
Results of this ﬁnal model are presented. Potential risk factors were checked
for proportional hazards by using a time-dependent covariate approach, and
a stratiﬁed model was used when there were nonproportional hazards.
First-order interactions between time period of transplantation and other
variables were assessed. P values are 2 sided. Analyses were performed
using SAS software (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Our ﬁnal cohort consisted of 15,059 patients who had
received their ﬁrst unrelated donor HCT using either PBSC or
bone marrow between 2000 and 2009. There were 1920
patients ages < 18 years with malignant diseases; 9575 ages
18 to 59 years with malignant diseases; 2194 ages 60 years
with malignant diseases; and 1370 with nonmalignant dis-
eases (Table 1).
Over the decade ranging from 2000 to 2009, there was a
141% increase in the number of unrelated donor HCT (963
HCT in 2000 compared with 2318 HCT in 2009). The number
of unrelated donor HCT increased in all 4 cohorts, but the
most dramatic increase was seen in the age 60 years ma-
lignant disease cohort (an increase from 33 transplantations
in 2000 to 574 transplantations in 2009), reﬂecting the
introduction and increased utilization of NMA/RIC regimens.
Patient, donor, and transplantation practices evolved
during the observation period (Table 1). After 2005, patients
were less likely to have high-risk disease and more likely to
receive their transplantation within 6 months of diagnosis.
Donors were more likely to provide PBSC as a graft source,
especially in patients 18 to 59 years old with malignant
disease. The proportion of donors who were matched to the
patient for the 8 most clinically relevant HLA loci (A, B, C, and
DR) increased signiﬁcantly. More patients who underwent
transplantation in the latter time period had coexisting dis-
eases/comorbidities at the time of transplantation. Trans-
plantation practices also evolved. First, after 2005, patients
were more likely to receive less toxic, nontotal body irradi-
ation conditioning regimens. Second, GVHD prophylaxis
choices shifted; the use of cyclosporine-based GVHD pro-
phylaxis declined coincident with increased use of
tacrolimus-based GVHD prophylaxis. Simultaneously, in vivo
T cell depletion increased, especially for malignant diseases,
whereas the use of ex vivo T cell depletion declined over
time.Outcomes in Patients Ages <18 Years with Malignant
Diseases
Three-year probabilities of survival, NRM, and relapse
were signiﬁcantly better after 2005 in children with malig-
nant disease (Table 2, Figure 1). The 10% absolute improve-
ment in 3-year survival (45% to 55%, P< .001) is explained by
signiﬁcant decreases in both NRM (27% to 21%, P < .001) and
relapse (33% to 27%, P ¼ .007). Because GVHD is the major
cause of NRM, we tested for differences in the incidence of
acute and chronic GVHD between the 2 time periods. The
100-day cumulative incidence of moderate to severe grade 2
to 4 acute GVHD (47% versus 41%, P ¼ .01) and severe grade 3
to 4 acute GVHD (23% versus 16%, P ¼ .001) was signiﬁcantly
lower in themore recent time period. The 2-year incidence of
chronic GVHD increased (39% versus 44%, P ¼ .03) but was
not sufﬁcient to offset the improvements in 3-year outcomes.
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N.S. Majhail et al. / Biol Blood Marrow Transplant 21 (2015) 142e150146We considered the possibility that the observed im-
provements in outcomes were a result of the signiﬁcantly
lower proportion of patients with high-risk disease or the
signiﬁcantly increased use of well-matched donors after
2005. Therefore, we examined unadjusted outcomes in the
following 3 relatively homogeneous subgroups: patients
with standard-risk disease, patients with high-risk disease,
and recipients of HLA 8/8ematched grafts (Table 3). NRM
signiﬁcantly decreased by a similar degree for patients with
standard-risk and high-risk disease, which translated into
signiﬁcantly improved survival for both of these subgroups.
This ﬁnding suggests that fewer high-risk disease trans-
plantations is insufﬁcient to explain the gains in survival.
NRM did not change in recipients of HLA 8/8ematched
grafts, which suggests that increasing the proportion of
transplantation from matched donors did contribute to the
improved outcomes observed. We further explored these
issues in the multivariate analyses below.
Outcomes in Patients Ages 18 to 59 Years with Malignant
Diseases
The 3-year probability of survival signiﬁcantly improved
over time (35% to 42%, P < .001) in this group (Table 2,
Figure 1). The 7% improvement in survival is entirely
explained by a 9% decrease in NRM (37% versus 28%, P <
.001), which was partially offset by a 2% increase in relapse
(32% versus 34%, P¼ .02). Similar towhat was observed in the
pediatric malignant disease cohort, we observed a reduction
in the 100-day cumulative incidence of grade 3 to 4 acute
GVHD (24% versus 19%, P < .001), even though there was
virtually no change in the incidence of grade 2 to 4 acute
GVHD (45% versus 44% P ¼ .41). As in the pediatric popula-
tion, the observed increase in 2-year cumulative incidence of
chronic GVHD (46% versus 57% P < .001) was not of a sufﬁ-
cient magnitude to offset the improvements in 3-year
outcomes.
Again, we performed additional analyses in homogenous
subgroups. Patients were divided into standard- and high-
risk disease groups as before. However, unlike children
where NMA/RIC regimens are not common but might impact
both NRM and relapse risks, in this age group, we also
accounted for conditioning regimen intensity in these strata.
Furthermore, there were sufﬁcient numbers of patients to
assess whether improvements in outcomes occurred in both
well-matched (8/8 HLAematched) and single-allele-
mismatched (7/8 HLAematched) transplantations. For
these latter subgroups, we created the most homogenous
groups possible, given the numbers of patients available.
Thus, we restricted these analyses to patients with AML,
CML, or MDS only (Table 3). NRM improved signiﬁcantly in
all subgroups except recipients of NMA/RIC with standard-
risk disease, whose NRM rates were already relatively low.
None of the subgroups demonstrated a reduction in the
cumulative incidence of relapse over time. In fact, recipients
of myeloablative conditioning with standard-risk disease
experienced an unexpected higher relapse rate (21% to 25%,
P ¼ .002). Hence, survival improvements were only seen in
subgroups with a substantial (9% to 10%) decrease in NRM.
Outcomes in Patients Ages  60 Years with Malignant
Diseases
The 3-year probability of survival in this cohort also
signiﬁcantly improved over time (Table 2, Figure 1). Unlike
that found in other age cohorts, however, the 10% absolute
improvement in 3-year survival (25% to 35%, P < .001) was
N.S. Majhail et al. / Biol Blood Marrow Transplant 21 (2015) 142e150 147primarily explained by a large reduction in the cumulative
incidence of relapse (46% versus 39%, P¼ .01). Improvements
in NRM were not statistically signiﬁcant (35% versus 31%,
P ¼ .19) which may be due, in part, to a lack of improvement
in the cumulative incidence of acute grade 2 to 4 GVHD (36%
versus 38%, P ¼ .51) or acute grade 3 to 4 GVHD, (17% versus
15%, P ¼ .45). As in the other cohorts, the 2-year cumulative
incidence of chronic GVHD was signiﬁcantly higher in the
most recent time period (45% versus 56%, P< .001). Although
the number of patients 60 years increased dramatically
during 2000 to 2009, we were only able to create 1 ho-
mogenous group for further analysisdNMA/RIC HCT re-
cipients with malignant disease (excluding plasma-cell
disorders and solid tumors). In this more homogenous
population, outcomes were similar to those seen in the larger
cohort (Table 3).
Outcomes in Patients with Nonmalignant Diseases
Patients with nonmalignant diseases had the best survival
among all 4 cohorts. Similar to other cohorts, overall survival
at 3 years improved signiﬁcantly over time (60% to 69%, P <
.001) in this group (Table 2, Figure 1). This was also reﬂected
by analyses restricted to homogeneous subsets of pediatric
patients (data not shown). Survival rates for adult patients
with severe aplastic anemia (58% to 64%, P ¼ .27) were not
signiﬁcantly different (Table 3). We did not observe a sig-
niﬁcant decrease in the cumulative incidence of acute grade
2 to 4 GVHD (33% versus 28%, P ¼ .07) or acute grade 3 to 4
GVHD (18% versus 14%, P ¼ .10). The cumulative incidence of
chronic GVHD at 2 years was also not signiﬁcantly different
(33% versus 37%, P ¼ .11).
Multivariate Analyses
We examined the association of time period of trans-
plantation with outcomes in multivariate models that
adjusted for all patient and transplantation risk factors
available (Table 4). We performed this analysis in a relatively
homogenous subset of patients with AML, acute lympho-
blastic leukemia, CML, and MDS who received their trans-
plant from HLA 8/8 or 7/8-matched donors. Patients whoFigure 1. Overall survival at 3 years for (A) age <18 years, malignant diseases, (B) age
(D) nonmalignant diseases.underwent transplantation after 2005 continued to experi-
ence better survival and lower NRM even after adjustment
for these other risk factors (see Supplemental Materials).
Interestingly, the NRM beneﬁt from a more recent trans-
plantation was limited to the ﬁrst 12 months after HCT
(hazard ratio, .65; P < .001). This early beneﬁt was partially
offset by an increase in NRM risk after 12 months, which
suggests that some of the changes in practices delayed,
rather than prevented, mortality. Furthermore, in this subset
analysis, after accounting for these risk factors, we found no
difference in risk of relapse for patients who underwent
transplantation more recently (hazard ratio, .99; P ¼ .816).
DISCUSSION
A major strength of this study is that the inclusion of
nearly all unrelated donor HCT in the United States provided
sufﬁcient statistical power to permit restricting the analysis
to the most recent decade with 3-year follow-up. Substantial
improvement in survival has occurred after unrelated donor
HCT over a relatively short time span (since 2005). The ab-
solute survival improvement of 7% to 10% at 3 years is clin-
ically meaningful. Deaths are relatively uncommon after
3 years [17], and a substantial number of patients alive at
3 years are potentially cured by unrelated donor HCT. Pre-
vious reports showed that HCT survival after 2000was better
than survival in the 1990s [18,19]. This present study shows
that survival has not only continued to improve, it has done
so even when compared with the recent past.
In this study, improvement in survival after unrelated
donor HCT for children and adults <60 years of age was
primarily a result of decreases in NRM. Multiple factors
explain the signiﬁcant improvements observed. These
include better matching technologies, increased use of NMA/
RIC regimens, and better control of severe acute GVHD. The
beneﬁt of undergoing transplantation in the more recent era
appears to be mainly driven by a decrease in nonrelapse-
related deaths in the ﬁrst 12 months after HCT, and late
deaths offset some of the early gains. This may be due to
more chronic GVHD associated with the greater use of PBSC
as a graft source. Although speculative, this concern was also18 to 59 years, malignant diseases, (C) age  60 years, malignant diseases, and
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N.S. Majhail et al. / Biol Blood Marrow Transplant 21 (2015) 142e150148raised by a recent randomized clinical trial that found
signiﬁcantly greater rates of chronic GVHD with the use of
PBSC from unrelated donors [20].
Our ﬁndings also reﬂect the advances in patient selection,
transplantation technology, and supportive care practices
over the past decade that have made HCT safer. Patients who
underwent transplantation more recently had better perfor-
mance status and lower disease risk, and they received HCT
earlier in their disease course. A substantially greater pro-
portion of patients usedHLA-matched unrelated donors in the
later time period in all 4 cohorts. This is a direct reﬂection of
advances in HLA typing and a greater availability of well-
matched donors who have been typed using high-resolution
DNA sequence-based methods. For example, the NMDP’s Be
The Match Registry presently includes approximately 12
million donors, comparedwith only 4million in 2000.We also
observed a notable decrease in the use of total body irradia-
tion as part of myeloablative conditioning regimens, which
likely has decreased transplantation-related toxicity. The
greatest increase in unrelated donor HCT utilization occurred
in the older patient cohort. This reﬂects the now routine use of
NMA/RIC regimens, which were introduced in the 1990s,
which allow HCT in older recipients and in patients with
comorbidities with acceptable risks of complications and
NRM. Indeed, we observed an increase in the number of pa-
tients who underwent transplantation who had coexisting
diseases and comorbidities at the time of HCT in 2005 to 2009
compared with those who underwent transplantation from
2000 to 2004. Survival, NRM, and relapse probabilities for the
older age group in our study are comparable to what has been
reported in the literature recently and should reassure clini-
cians about the improvement in outcomes of unrelated donor
HCT in this population [21,22].
Our study has the usual limitations of a registry-based
retrospective cohort study. Our study population was high-
ly heterogeneous and included a wide spectrum of di-
agnoses, conditioning, and GVHD prophylaxis regimens.
However, these broad inclusion criteria represent the “real
world” practice of HCT and highlight the generalizability of
our ﬁndings. To enhance the utility of this report, we con-
structed subgroups that represent some common scenarios
(eg, adults with standard-risk malignancy) encountered by
physicians in clinical practice and provide current 3-year
survival, NRM, and relapse rates. It is our hope that clini-
cians will ﬁnd these statistics useful when counseling pa-
tients regarding treatment options. We did not compare the
results of our cohort with patients receiving HLA-identical
sibling donor HCT, although for some diseases, survival af-
ter HLA-matched unrelated and HLA-identical sibling donor
transplantation has been shown to be comparable [5-10].
In summary, signiﬁcant improvement in survival after
unrelated donor HCT has occurred over the past decade for
all patient groups. Advances in patient selection and prac-
tices, such as HCT earlier in the disease course, availability of
better matched donors, safer conditioning regimens, and
improved supportive care have contributed to this
improvement. Our ﬁndings should reassure clinicians and
patients about the efﬁcacy of unrelated donor HCT for pa-
tients in need of HCT who do not have a suitable HLA-
identical sibling donor, and these patients should be
referred to a transplantation center early in their disease
course. Outcomes achieved with other alternative donor
sources, such as umbilical cord blood and haploidentical
donors, should be compared with the new baseline estab-
lished in this study.
Table 4
Results of Multivariate Analyses Evaluating the Association of Time Period
with Outcomes in a Subset of Patients with AML, ALL, CML, and MDS Who
Received Unrelated Donor Transplants from HLA 8/8 or 7/8eMatched
Donors
Outcomes n Hazard Ratio
(95% CI)
P Value
Overall mortality*,y
Early effect (12 mo after
transplantation)
2000-2004 2574 1.00 <.001
2005-2009 5957 .77 (.72-.83)
Late effect (>12 mo after
transplantation)
2000-2004 1320 1.00 <.001
2005-2009 3459 1.29 (1.14-1.46)
NRM*,z
Early effect (12 mo after
transplantation)
2000-2004 2467 1.00 <.001
2005-2009 5751 .65 (.58-.72)
Late effect (>12 mo after
transplantation)
2000-2004 1093 1.00 <.001
2005-2009 2948 1.56 (1.28-1.90)
Relapsex
2000-2004 2467 1.00 .816
2005-2009 5751 .99 (.90-1.08)
* Nonproportional hazards (hazard ratios were different for  12 months
and > 12 months after transplantation).
y Other factors signiﬁcantly associated with overall mortality included
recipient age, recipient sex, recipient ethnicity/race, Karnofsky/Lansky sta-
tus at transplantation, recipient CMV status, coexisting disease, diagnosis,
disease risk (malignancies), time from diagnosis to transplantation, HLA
match, and GVHD prophylaxis regimen.
z Other factors signiﬁcantly associated with NRM included recipient age,
recipient sex, recipient ethnicity/race, Karnofsky/Lansky status at trans-
plantation, recipient CMV status, coexisting disease, diagnosis, disease risk
(malignancies), time from diagnosis to transplantation, HLA match, and
GVHD prophylaxis regimen.
x Other factors signiﬁcantly associated with relapse included recipient
age, Karnofsky/Lansky status at transplantation, coexisting disease, diag-
nosis, disease risk (malignancies), time from diagnosis to transplantation,
and GVHD prophylaxis regimen.
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